Objectives: To compare mortality rates for Indigenous and non-Indigenous Australians commencing renal replacement therapy (RRT) over time and by categories of remoteness of place of residence.
Results: Indigenous patients were younger, more likely to have diabetes, be referred late and be from a more remote area than non-Indigenous patients. Age and comorbid conditions increased with successive cohorts for both groups. Unadjusted analysis (using the log-rank test) showed an increased risk of death for Indigenous patients in the [1995] [1996] [1997] [1998] [1999] Conclusions: Although unadjusted analysis suggests that the survival gap between Indigenous and non-Indigenous patients receiving RRT has closed, there remains a significant disparity in survival after adjusting for the variables considered in our study. A boriginal and Torres Strait Islander people (respectfully referred to hereafter as Indigenous Australians) have a higher incidence of end-stage kidney disease requiring renal replacement therapy (RRT) than non-Indigenous Australians.
Survival of Indigenous
1,2 A high proportion of Indigenous patients come from rural and remote areas, 3 which are associated with markers of poorer socioeconomic status. 4 They are more likely to receive haemodialysis and much less likely to receive a kidney transplant than non-Indigenous Australians. 1, 5 In the past 10 years, there have been concerted efforts across Australia to provide dialysis services in more remote areas. 6 While providing support for self-care home haemodialysis and peritoneal dialysis in remote Australia has been challenging, [7] [8] [9] haemodialysis units supported by nurses have been established in small towns and communities. The impact of remoteness on quality of life for Indigenous RRT patients has been well described, 10 but its effect on survival has not. We do know that there is a small increase in the risk of death associated with increasing remoteness for non-Indigenous people receiving RRT. 11 Emerging evidence in reports on the outcomes of RRT for Indigenous Australians suggests that there has been a significant gap in survival between Indigenous and non-Indigenous Australians in the past, 12, 13 but that this may have been narrowing. 14 Past studies have predated service delivery changes, concentrated on specific regions only 12, 15 or examined dialysis modalities and transplant survival separately [16] [17] [18] rather than consider the outcome from the start of treatment for all patients regardless of their initial or subsequent RRT modality.
In this registry-based study, we sought to describe all-cause mortality for Indigenous Australians commencing RRT over time, taking remoteness into account, and to compare this with all-cause mortality for non-Indigenous Australians commencing RRT.
Methods

Study population
The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects observational data on all patients receiving chronic RRT in Australia and New Zealand; these data are submitted by treating renal units. This study included all patients aged 15 years or more who commenced RRT between 1 January 1995 and 31 December 2009 and who were maintained on RRT for more than 90 days to create three equal 5-year period-inception cohorts (1995-1999, 2000-2004, 2005-2009 , inclusive). Patients were followed until 31 December 2011. We compared Indigenous Australians (those who self-identify as being of Aboriginal or Torres Strait Islander origin) with non-Indigenous Australians (including those of any other ethnicity who commenced RRT in Australia).
Data collection
Comorbid conditions reported at commencement of RRT included coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease and diabetes. Comorbid conditions were recorded in three categories: no, yes or suspected. For this analysis, "no" and "suspected" were combined. Body mass index (BMI) was calculated from height and weight data at commencement of RRT. Late referral was defined as commencing RRT within 3 months of being referred to a nephrologist and data were collected from 1 April 1995.
Postcode data at commencement of RRT were collected from 1 April 1995. An Australian Bureau of Statistics correspondence file 19 was used to map postcodes onto the Accessibility and Remoteness Index of Australia (ARIA+), a system based on the physical distance by road from each location point to the nearest town or service centre. This creates a five-category classification of remoteness: major cities, inner regional, outer regional, remote and very remote areas.
Statistical analyses
The outcome for the study was allcause mortality. Patient data were censored at 5 years after commencement of RRT, at the date of recovery of renal function or at the date of last known follow-up if they had not died previously.
The probability of survival to 5 years after the commencement of RRT was assessed by calculating KaplanMeier failure curves 20 with groups compared by the log-rank test.
Using the Cox proportional hazards (PH) model, analysis of the hazard of death was performed using interaction terms between Indigenous status and cohort, and Indigenous status and remoteness category. Variables were added to this model to determine which contributed most to the outcome of the final model. Explanatory variables included cohort, Indigenous status, age, sex, comorbid conditions, BMI categories, late referral and remoteness category. Interactions between variables thought likely based on knowledge of the literature were modelled; the difference in calculated effect on the hazard ratio was less than 20% for all those assessed. For all Cox PH models, the Efron method was used for resolving ties and the PH assumption was assessed by two different graphical means.
21 Sensitivity analysis was conducted considering only confirmed comorbid conditions compared with both confirmed and suspected comorbid conditions combined on the outcome of the full Cox PH model. Indigenous patients commencing RRT were 10-12 years younger and more likely to be female and to have diabetes than non-Indigenous patients. Indigenous patients were more likely to have lower levels of endogenous kidney function at commencement of RRT, to be "late referred", and to come from outer regional, remote or very remote regions than non-Indigenous patients. Far fewer Indigenous patients received kidney transplants in the first 5 years of treatment.
There were also important differences between cohorts for both Indigenous and non-Indigenous patients. Compared with the earliest cohort, patients in later cohorts were older, more likely to be male and more likely to have diabetes or coronary artery disease. Later cohorts also had a higher proportion of overweight and a lower proportion of underweight patients, and mean endogenous kidney function was higher. Of particular note, the rise in age for non-Indigenous patients was greater than that for Indigenous patients.
Years of follow-up, the number of deaths and the death rate for each cohort and patient group are shown in Box 2, and Kaplan-Meier failure curves are shown in Box 3. The logrank test confirmed a significant difference in the risk of death between Indigenous and non-Indigenous patients for 1995-1999 (P = 0. Box 5 shows the impact of the Indigenous-cohort interaction on the mortality hazard. Adjusting for all other variables, the mortality risk improved for both non-Indigenous and Indigenous patients over time. However, the risk was higher in all cohorts for Indigenous compared with non-Indigenous patients in each remoteness category (Box 4): the cohort interaction terms were not statistically significant (χ 2 = 1.14; df = 2; P = 0.6).
The Indigenous-remoteness interaction terms are highlighted in Box 6. Although non-Indigenous patients from major capital cities had a lower hazard than non-Indigenous patients from other regions, this was not the case for Indigenous patients (Box 4); however, the remoteness category interaction terms were not significant overall (χ 2 = 6.17; df = 4; P = 0.2).
Discussion
In this analysis of all people commencing RRT in Australia from 1995 to 2009, we found that there was a survival difference between Indigenous and non-Indigenous patients in the past that appears to have closed more recently when assessed by methods without adjustment for the substantial differences in the patient populations.
With adjustment (particularly for age and diabetes), it became apparent that survival for both Indigenous and non-Indigenous patients has indeed improved over time despite an increasing burden of comorbid conditions. However, the gap in survival between Indigenous and non-Indigenous patients has not narrowed.
The use of interaction terms allowed us to incorporate into one model factors of interest that may affect Indigenous and non-Indigenous patients differently. While increasing the complexity of the analysis, this enabled us to explore how any disparity between Indigenous and non-Indigenous patients varies over time and remoteness categories. By doing so, we have shown not only that a difference in adjusted risk of death continues between Indigenous and non-Indigenous patients, but also that this difference has been maintained over the past 15 years in the face of improvements in both nonIndigenous and Indigenous survival.
In addition, we have shown that that the relationship between remoteness category and mortality is different for Indigenous and nonIndigenous patients. For all cohorts, an Indigenous patient from a major capital city had a greater risk of death than a similar non-Indigenous patient; differences for other regions are less apparent. The variation in the risk of death by remoteness for non-Indigenous patients remains similar to previously published findings. 11 Despite efforts to provide dialysis treatments closer to home in recent years, the risk of death for Indigenous patients from very remote areas remains higher than for those in major cities (Box 6).
When interpreting the results of the fully adjusted Cox PH model, it is important to remember that the Indigenous and non-Indigenous patient populations remain quite different, and that they both have changed over the period studied. For example, while the hazard ratio for diabetes applies equally to both groups, up to 79.4% of Indigenous patients have diabetes compared with rates half that or less for nonIndigenous patients. Similar differences exist for many other measured variables, particularly late referral (which remains more likely for Indigenous patients despite recent improvements) and age (which has become increasingly older in the non-Indigenous population over the period of the study) (Box 1). The difference between Indigenous and non-Indigenous survival is smaller if transplantation is considered separately (data not shown), suggesting that the lower transplant rate for Indigenous patients may be contributing to their higher risk of death after starting RRT, poorer outcomes notwithstanding. 16, 17 Since fewer Indigenous patients receive transplants, it is reasonable to assume that those few who do are carefully selected and that those Indigenous patients remaining on dialysis will include a number who may well have had a transplant if they were nonIndigenous. This latter group may have a better prognosis than other patients being treated by dialysis. To avoid this susceptibility bias, for our initial analysis, we assessed survival by pooling all patients together regardless of their initial or subsequent treatment modality, as was done in previous studies.
22,23 Treatment modalities were not included as a term in any Cox PH models for the same reason. As a result, this study adds to previous work [12] [13] [14] [15] [16] [17] [18] more recent data that are national in scope and encompass all RRT modalities.
The increased hazard for death for Indigenous patients receiving RRT, once other baseline variables recorded within ANZDATA are taken into consideration, requires explanation. Of note, similar studies from overseas examining survival differences for people starting RRT have shown better adjusted survival rates for those from minority groups, 23, 24 or at least equal survival in the case of aboriginal patients from the Prairie Provinces of Canada. 22 Many Indigenous Australians receiving RRT come from more remote settings than these overseas minority groups, but this does not explain the persistent increased hazard of death for Indigenous Australians from major capital cities. There may be different patterns of referral for RRT in different countries, although in all those quoted, the costs of RRT are covered by some form of national health insurance. The much lower likelihood of Indigenous Australian patients receiving a kidney transplant compared with non-Indigenous Australians accounts for only some of the difference between the two groups.
There are limitations inherent in this study. Data on characteristics such as social and economic circumstances that may confound Indigenous status are not collected within ANZDATA and are challenging to tease out even with existing Australian Bureau of Statistics Census area data. 25 It is possible that the recorded postcode of residence for Indigenous people is inaccurate. 3 Comorbidity data captured in ANZDATA are imperfect, in part because they are based on the opinion of the treating physician rather than objectively defined criteria. There is also no information on the severity of comorbid conditions. The analysis examined baseline characteristics only, rather than changes in comorbidity over time. This approach was taken to provide useful information to clinicians discussing prognosis with patients considering RRT.
The improving underlying probability of survival for both Indigenous and non-Indigenous patients starting RRT, once recorded factors are considered, makes the use of these data for predicting survival patterns challenging. Nevertheless, it is sobering to consider that the risk of death after starting RRT still outstrips that for many other diseases, including many cancers (Box 3). As a result, the highest priority must be to prevent as many people as possible (both Indigenous and non-Indigenous) from developing end-stage kidney disease in the first place. 
